Bromantane

WHAT IT IS

Bromantane, also called bromantan or adamantylbromophenylamine, is a synthetic small molecule in the adamantane family, structurally related to amantadine and memantine but pharmacologically distinct from both.

It was developed in Russia and is sometimes described as an actoprotector, a Soviet-era term for compounds intended to improve physical and mental endurance without the crash pattern associated with typical stimulants.

In Russia it is a prescription medication marketed as Ladasten for asthenic and anxious-asthenic disorders, sold as 50 mg and 100 mg tablets.

FDA status: Bromantane is not FDA-approved for any indication in the United States; it holds prescription approval in Russia under the Ladasten brand.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published work, concentrated in Russian clinical literature and some smaller international reports, has looked at:

• Asthenic and anxious-asthenic disorders, meaning persistent fatigue with reduced stress tolerance
• Recovery of endurance and reduced fatigue during sustained physical or cognitive workload
• Dopaminergic signaling and its relationship to motivation and activation
• Anxiolytic-like effects reported alongside activating effects, an unusual combination
• Limited healthy-volunteer studies examining cognitive task performance

PROPOSED BIOLOGICAL MECHANISMS

Bromantane is proposed to increase dopamine release from presynaptic terminals, reduce its reuptake, and enhance dopamine biosynthesis through effects on tyrosine hydroxylase gene expression.

Serotonergic signaling has also been implicated, which researchers suggest may help explain the reported anxiolytic component alongside the activating, pro-endurance effects.

Unlike classic stimulants, bromantane is described in Russian pharmacology literature as lacking the marked hyperstimulation and post-use exhaustion associated with amphetamine-type compounds, though this description comes largely from the developer's own literature rather than independent replication.

AREAS OF RESEARCH INTEREST

• Whether the antiasthenic effects reported in Russian trials replicate under independent, internationally standard trial design
• Whether cognitive or performance benefits exist beyond relief of fatigue and low mood in asthenic patients
• The compound's abuse and dependence potential given its dopaminergic activity
• Why the compound has almost no footprint in Western regulatory or research literature despite decades of Russian clinical use

WHAT THE EVIDENCE CURRENTLY SUGGESTS

A small placebo-controlled Russian trial and a larger uncontrolled clinical report both described faster improvement in asthenic symptoms with oral Ladasten compared with baseline or comparator treatment.

A small healthy-volunteer study found no clear improvement in core cognitive task performance, suggesting any benefit may be concentrated in people with baseline fatigue or asthenic symptoms rather than in unimpaired individuals.

The evidence base sits almost entirely within Russian-language clinical literature, with very little independent replication published in international, peer-reviewed journals outside that circle.

Bromantane also appears on the World Anti-Doping Agency's prohibited list as an in-competition stimulant, which is a regulatory and competitive-sport fact rather than a therapeutic claim.